Our Promise
We will help our partners prevail in their mission to develop needed therapies. We will ensure that high-quality development and imperative urgency remains our focus.
How We Help
Launch Therapeutics offers pharmaceutical and biotech partners a variety of innovative models that provide capital, development expertise, and access to additional resources. These models offer an aligned and efficient approach to help finance and develop late-stage therapies and accelerate the path to regulatory approval. Launch Tx’s team of experts bring an unrivaled combination of immense commitment, decades of experience, and enthusiastic passion to their work.
Сapital
Bespoke deal structures taking combination of clinical, regulatory, and commercial risks
Resources
Team with deep clinical and regulatory expertise with access to an expansive network
Acceleration
Disruptive model accelerating clinical development and regulatory timelines
In The News
Pathalys Pharma and Launch Therapeutics Announce First Patient Enrolled Ahead of Schedule in Pivotal Phase 3 Program for Upacicalcet in Patients Receiving Hemodialysis
Research Triangle Park, North Carolina and Boston, Massachusetts, May 31, 2023 – Pathalys Pharma, Inc., a private, late-stage biopharma company co-founded by Catalys Pacific and DaVita Venture Group, and Launch Therapeutics (Launch Tx), a clinical development company, today announced that the first patient has been enrolled in the PATH (PTH Attenuation Trial in Hemodialysis) clinical program, consisting of two identical phase 3 trials, to assess upacicalcet for the treatment of secondary hyperparathyroidism (SHPT) in end-stage kidney disease (ESKD) patients on hemodialysis.